Targeting BTK in CLL: Expert Guidance on Selecting Single-Agent and Combination Therapy

Join us for a live interactive webinar to learn more about the use of BTK inhibitors in patients with CLL, the differences between first and next generation BTK inhibitors, planning the optimal therapy, evaluating ongoing clinical trials, and managing adverse events. This webinar will offer attendees the opportunity to have their questions answered by an expert panel.

Agenda

*Date and Time: Wednesday, October 27, 2021 from 17:00 - 18:00 CET

Welcome, Introduction, and Baseline Assessment

The Current Role of BTK Inhibitors in CLL

Case Discussions: Practical Guidance on Selecting BTK inhibitor

Therapy in CLL

Summary, Final Thought, Audience Q&A

Events

Date / Time
Event Details

Faculty

Faculty
Seema Bhat, MD

Hematologist
The Ohio State University Comprehensive Cancer Center–James
Columbus, Ohio, USA

Faculty
Talha Munir, MBBS, MRCP, FRCPath

Consultant Haematologist
Department of Haematology
St James's Hospital
Leeds, United Kingdom

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize the use of current and emerging therapeutic strategies with BTK inhibitors in the care of their patients with CLL.

Target Audience
This program is intended for global hematologists, oncologists, and other healthcare professionals involved in the management of patients using BTK inhibitors in the treatment of patients with CLL.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Discuss with patients differences between first- and next-generation BTK inhibitors in terms of molecular characteristics, selectivity, preclinical data, approved indications, dosing, safety profile, and efficacy
  • Plan optimal BTK inhibitor–based therapy for patients with CLL, taking into consideration guidelines, expert recommendation, and recent practice-changing clinical trial results
  • Recognize and manage adverse events and toxicities associated with BTK inhibitor therapy to support adherence, appropriate dosing, quality of life, and continuation of treatment
  • Evaluate ongoing clinical trials investigating available and emerging BTK inhibitors as single agents and in combination

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.